Rowe, Everton

Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial

Aroda, V. R., Bain, S. C., Cariou, B., Piletič, M., Rose, L., Axelsen, M., Rowe, E., & DeVries, J. H. (2017) · The Lancet Diabetes & Endocrinology

Diabetes Treatment and ManagementDiabetes Management and Research

Cited by 464

Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus

Fujioka, K., Seaton, T. B., Rowe, E., Jelinek, C. A., Raskin, P., Lebovitz, H. E., Weinstein, S. P., & Group, T. S. C. S. (2000) · Diabetes, Obesity and Metabolism

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 244

Absorption, metabolism and excretion of the GLP-1 analogue semaglutide in humans and nonclinical species

Jensen, L., Helleberg, H., Roffel, A., van Lier, J. J., Bjørnsdottir, I., Pedersen, P. J., Rowe, E., Derving Karsbøl, J., & Pedersen, M. L. (2017) · European Journal of Pharmaceutical Sciences

Diabetes Treatment and ManagementPharmacogenetics and Drug Metabolism

Cited by 182